Clinical Trial: A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07265479) titled 'A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis' on Nov. 21.

Brief Summary: The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: Tapinarof cream, 1%

Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will ...